Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib in MCAP (SESAM)
NCT05577754Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Nov 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started Nov 2022; status: recruiting.
02
Drugs
alpelisib
03
Conditions
megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP)
Beyond the preview
Go deeper on NCT05577754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577754.